DPX-Survivacの市場規模、予測、新薬の考察（ 2032年）

薬剤のサマリー

Immunvaccineが開発中のMaveropepimut-S（MVP-S、旧称DPX-Survivac）は、DPXプラットフォームとがん抗原サバイビンを組み合わせたT細胞活性化免疫療法です。これは、生体内で標的T細胞を生成するIMVの新しいクラスの免疫療法のリード臨床候補です。サバイビン特異的キラーT細胞を活性化することにより、Maveropepimut-Sはがん細胞の破壊を促進し、がん細胞の生成と生存の基本的プロセスを破壊します。DPX-Survivacは、Merck KGaAから全世界独占的にライセンスされたサバイビンベースの抗原を使用し、DepoVaxワクチンデリバリープラットフォームで製剤されます。

現在、プラチナ製剤抵抗性上皮性卵巣がんを対象としたフェーズII臨床試験（AVALON）が実施されており、2025年8月までに完了する見込みです。

当レポートでは、主要7市場（米国・ドイツ・フランス・イタリア・スペイン・英国・日本）における卵巣がん向けDPX-Survivacについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。

目次

第1章 レポートのイントロダクション

第2章 卵巣がんにおけるDPX-Survivacの概要

• 製品の詳細
• 臨床開発
  • 臨床研究
  • 臨床試験情報
  • 安全性と有効性
• その他の開発活動
• 製品プロファイル

第3章 競合情勢（上市済みの治療法）

第4章 競合情勢（後期の新治療法）

第5章 DPX-Survivac市場の評価

• 卵巣がんにおけるDPX-Survivacの市場見通し
• 主要7市場の分析
  • 主要7市場の卵巣がん向けDPX-Survivacの市場規模
• 市場の分析：国別
  • 米国の卵巣がん向けDPX-Survivacの市場規模
  • ドイツの卵巣がん向けDPX-Survivacの市場規模
  • 英国の卵巣がん向けDPX-Survivacの市場規模

第6章 SWOT分析

第7章 アナリストの見解

第8章 付録

第9章 DelveInsightのサービス内容

第10章 免責事項

第11章 DelveInsightについて

第12章 レポート購入オプション

List of Tables

• Table 1: DPX-Survivac, Clinical Trial Description, 2023
• Table 2: DPX-Survivac, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Late-stage Emerging Therapies)
• Table 5: DPX-Survivac Market Size in the 7MM, in USD million (2019-2032)
• Table 6: DPX-Survivac Market Size in the US, in USD million (2019-2032)
• Table 7: DPX-Survivac Market Size in Germany, in USD million (2019-2032)
• Table 8: DPX-Survivac Market Size in France, in USD million (2019-2032)
• Table 9: DPX-Survivac Market Size in Italy, in USD million (2019-2032)
• Table 10: DPX-Survivac Market Size in Spain, in USD million (2019-2032)
• Table 11: DPX-Survivac Market Size in the UK, in USD million (2019-2032)
• Table 12: DPX-Survivac Market Size in Japan, in USD million (2019-2032)

List of Figures

• Figure 1: DPX-Survivac Market Size in the 7MM, USD million (2019-2032)
• Figure 2: DPX-Survivac Market Size in the United States, USD million (2019-2032)
• Figure 3: DPX-Survivac Market Size in Germany, USD million (2019-2032)
• Figure 4: DPX-Survivac Market Size in France, USD million (2019-2032)
• Figure 5: DPX-Survivac Market Size in Italy, USD million (2019-2032)
• Figure 6: DPX-Survivac Market Size in Spain, USD million (2019-2032)
• Figure 7: DPX-Survivac Market Size in the United Kingdom, USD million (2019-2032)
• Figure 8: DPX-Survivac Market Size in Japan, USD million (2019-2032)

"DPX-Survivac Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about DPX-Survivac for ovarian cancer in the seven major markets. A detailed picture of the DPX-Survivac for ovarian cancer in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the DPX-Survivac for ovarian cancer. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the DPX-Survivac market forecast analysis for ovarian cancer in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in ovarian cancer.

Drug Summary:

Maveropepimut-S (MVP-S, previously known as DPX-Survivac), being developed by Immunvaccine, is a T cell activating immunotherapy that combines the power of DPX Platform with cancer antigen survivin. It is the lead clinical candidate in IMV's new class of immunotherapies that generates targeted T cells in vivo. By activating survivin-specific killer T cells, maveropepimut-S promotes the destruction of cancer cells and disrupts the fundamental processes of cancer cell production and survival. DPX-Survivac uses Survivin-based antigens in-licensed from Merck KGaA on a worldwide exclusive basis and formulated in the DepoVax vaccine delivery platform.

It is currently being investigated in Phase II clinical trial (AVALON) for the potential treatment of platinum-resistant epithelial ovarian cancer that is estimated to be completed by August 2025.

Scope of the Report:

The report provides insights into:

• A comprehensive product overview including the DPX-Survivac description, mechanism of action, dosage and administration, research and development activities in ovarian cancer.
• Elaborated details on DPX-Survivac regulatory milestones and other development activities have been provided in this report.
• The report also highlights the DPX-Survivac research and development activities in ovarian cancer across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around DPX-Survivac.
• The report contains forecasted sales of DPX-Survivac for ovarian cancer till 2032.
• Comprehensive coverage of the late-stage emerging therapies for ovarian cancer.
• The report also features the SWOT analysis with analyst views for DPX-Survivac in ovarian cancer.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

DPX-Survivac Analytical Perspective by DelveInsight

• In-depth DPX-Survivac Market Assessment

This report provides a detailed market assessment of DPX-Survivac for ovarian cancer in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2027 to 2032.

• DPX-Survivac Clinical Assessment

The report provides the clinical trials information of DPX-Survivac for ovarian cancer covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

• In the coming years, the market scenario for ovarian cancer is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence DPX-Survivac dominance.
• Other emerging products for ovarian cancer are expected to give tough market competition to DPX-Survivac and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of DPX-Survivac in ovarian cancer.
• Our in-depth analysis of the forecasted sales data of DPX-Survivac from 2027 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the DPX-Survivac in ovarian cancer.

Key Questions:

• What is the product type, route of administration and mechanism of action of DPX-Survivac?
• What is the clinical trial status of the study related to DPX-Survivac in ovarian cancer and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the DPX-Survivac development?
• What are the key designations that have been granted to DPX-Survivac for ovarian cancer?
• What is the forecasted market scenario of DPX-Survivac for ovarian cancer?
• What are the forecasted sales of DPX-Survivac in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to DPX-Survivac for ovarian cancer?
• Which are the late-stage emerging therapies under development for the treatment of ovarian cancer?

Table of Contents

1. Report Introduction

2. DPX-Survivac Overview in ovarian cancer

• 2.1. Product Detail
• 2.2. Clinical Development
  • 2.2.1. Clinical studies
  • 2.2.2. Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies)

5. DPX-Survivac Market Assessment

• 5.1. Market Outlook of DPX-Survivac in ovarian cancer
• 5.2. 7MM Analysis
  • 5.2.1. Market Size of DPX-Survivac in the 7MM for ovarian cancer
• 5.3. Country-wise Market Analysis
  • 5.3.1. Market Size of DPX-Survivac in the United States for ovarian cancer
  • 5.3.2. Market Size of DPX-Survivac in Germany for ovarian cancer
  • 5.3.3. Market Size of DPX-Survivac in France for ovarian cancer
  • 5.3.4. Market Size of DPX-Survivac in Italy for ovarian cancer
  • 5.3.5. Market Size of DPX-Survivac in Spain for ovarian cancer
  • 5.3.6. Market Size of DPX-Survivac in the United Kingdom for ovarian cancer
  • 5.3.7. Market Size of DPX-Survivac in Japan for ovarian cancer

6. SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options